Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.44 |
| ▸ | HTR6 | P50406 | 3/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6087031 | 0.78 | IMPDH2 (0.46) | TSHRMAPK1IMPDH2MAPTPRKCA | |
| SCHEMBL31687177 | 0.78 | IMPDH2 (0.54) | MAPK1IMPDH2MAPTLMNAHTT | |
| SCHEMBL31687146 | 0.77 | BRPF1 (0.41) | IMPDH2HTR6MAPTMEN1KMT2A | |
| SCHEMBL6087921 | 0.74 | POLB (0.55) | TSHRMAPK1POLBIMPDH2HTR6 | |
| SCHEMBL31687076 | 0.74 | L3MBTL1 (0.43) | IMPDH2MEN1KMT2ALMNA | |
| SCHEMBL31687136 | 0.73 | TUBB1 (0.48) | — | |
| SCHEMBL1777994 | 0.73 | IMPDH2 (0.56) | POLBIMPDH2HTR6PDE4BMAPT | |
| SCHEMBL31687153 | 0.70 | CYP1A1 (0.54) | POLBIMPDH2MEN1KMT2A | |
| SCHEMBL6088237 | 0.69 | SRC (0.47) | IMPDH2 | |
| SCHEMBL6090667 | 0.69 | AR (0.46) | IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125906-B2 | Indole derivatives having anti-angiogenetic activity | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | claimed |
| US-20050159474-A1 | Angiogenesis inhibitors for cardiovascular disorders, neovascularization | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | US | claimed |
| EP-1515716-A2 | INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY | Astrazeneca AB (SE) | 2005-03-23 | — | — | EP | claimed |
| WO-2003082271-A2 | INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | claimed |
| US-7125906-B2 | Indole derivatives having anti-angiogenetic activity | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| US-20050159474-A1 | Angiogenesis inhibitors for cardiovascular disorders, neovascularization | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | US | disclosed |
| EP-1515716-A2 | INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY | Astrazeneca AB (SE) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003082271-A2 | INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159474-A1 | Angiogenesis inhibitors for cardiovascular disorders, neovascularization | FLT1, FLT4, VEGFA | TSHR 2854/4885MAPK1 921/4885POLB 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.